NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio
Fierce Pharma
NOVEMBER 16, 2022
NICE gives thumbs-down to 5 COVID-19 drugs including AZ's Evusheld and Merck's Lagevrio. kdunleavy. Wed, 11/16/2022 - 09:44.
Sat.Nov 12, 2022 - Fri.Nov 18, 2022
306 
Early cell therapy successes start to turn the tide in lupus
Pharmaceutical Technology
NOVEMBER 14, 2022
In a field dominated by antibodies and small molecules, two cell-therapy based approaches have come under the spotlight for showing early signs of efficacy in treating lupus. In September, a group from Friedrich Alexander University Erlangen-Nuremberg reported that five patients with lupus achieved remission after an infusion of autologous chimeric antigen receptor (CAR)-T cells led to a deep depletion of B cells.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Two Pharmacy Owners Plead Guilty in $18M Foreign Medicare Fraud Scheme
MedCity News
NOVEMBER 17, 2022
The scheme started in New York but became a complex international endeavor as the two men attempted to launder money received from fraudulent Medicare claims for cancer drugs during the pandemic.
Advanced therapies and the high-profile pricing dilemma
pharmaphorum
NOVEMBER 16, 2022
The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. However, alongside this progress, Ben Hargreaves finds that there is also a conundrum over how to price these therapies. It is no secret that the drug development process for the pharmaceutical industry has undergone a major transition in the last few decades.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Nothing to sneeze at: AstraZeneca donates thousands of nasal spray flu vaccines after Swiss pricing row
Fierce Pharma
NOVEMBER 17, 2022
Nothing to sneeze at: AstraZeneca donates thousands of nasal spray flu vaccines after Swiss pricing row. fkansteiner. Thu, 11/17/2022 - 13:27.
MHRA approves first gene therapy for infusion into the brain
European Pharmaceutical Review
NOVEMBER 18, 2022
Upstaza (eladocagene exuparvovec) is the first and only approved treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and is the first marketed gene therapy for direct infusion into the brain. The product, produced by biopharma company PTC Therapeutics, is approved for patients 18 months and over. It has been granted marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Data privacy concerns don’t hinder digital health app usage
pharmaphorum
NOVEMBER 15, 2022
A new survey conducted by juli, an AI-powered chronic condition platform, has revealed that the value placed on digital privacy differs widely among US users. With the HLTH 2022 event now well underway, digital health industry leaders all gathered together to attend in Las Vegas this week, the juli survey results reveal consumer responses to be more varied than one would have expected when it comes to data privacy.
Novartis targets eye, respiratory units for potential sell-offs after Sandoz: Bloomberg
Fierce Pharma
NOVEMBER 16, 2022
Novartis targets eye, respiratory units for potential sell-offs after Sandoz: Bloomberg. aliu. Wed, 11/16/2022 - 10:15.
Innovation in pharma manufacturing quality systems
European Pharmaceutical Review
NOVEMBER 16, 2022
As the emphasis of new drug development gravitates towards new, ground-breaking therapies and vaccines, the requirements of manufacturing sites, equipment and processes need to be appropriate for this new environment. For young biotechs, scaling up production brings green-field challenges, while for more established pharma a shift may be required to ensure that facilities are optimised for new ways of working.
Telehealth: A Boon for Treating Substance Use Disorder? Or a Risk?
MedCity News
NOVEMBER 13, 2022
While telehealth has provided many benefits throughout the pandemic, it can be a lonely and sterile way of receiving treatment. Individuals experiencing substance use disorder who only receive treatment through telehealth may miss opportunities to connect with others in support of the recovery process.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Novartis said to be eyeing sale of ophthalmology, respiratory units
pharmaphorum
NOVEMBER 16, 2022
Novartis has already spun out its eyecare business Alcon, and is now considering the sale of its ophthalmology and respiratory medicines businesses as it continues a narrowing of its focus, according to media reports. A Bloomberg article citing people close to the matter claims that Novartis is engaged in early discussions about the sale of the two units, which could raise billions of dollars in capital that could be reinvested into the pharma group’s pipeline.
Ardelyx FDA docs portend another showdown at this week's expert hearing on kidney disease prospect
Fierce Pharma
NOVEMBER 15, 2022
Ardelyx FDA docs portend another showdown at this week's expert hearing on kidney disease prospect. fkansteiner. Tue, 11/15/2022 - 10:30.
Implantable Device Adheres to Muscle, Treats Atrophy
Medgadget
NOVEMBER 16, 2022
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard have developed a mechanically active gel-elastomer-nitinol tissue adhesive, otherwise known as MAGENTA. The implantable device functions as a soft robot, and it can be adhered to the outside of a muscle. When an electrical charge is applied to the device, a spring inside made from nitinol (a shape memory alloy) heats up and begins to actuate, creating a contraction and stretching effect on the attached muscle.
Machine learning: An essential tool in the shift to risk-based quality management
MedCity News
NOVEMBER 16, 2022
Risk-based quality management is a data monitoring approach that accelerates the drug development pathway without compromising on safety – and one that is enhanced by the use of technologies such as artificial intelligence.
HLTH 2022 – Day 2
pharmaphorum
NOVEMBER 15, 2022
Early on Day 2, Matthew Holt (who we recently featured in our Health Innovators video series ) will interview Walmart EVP Dr. Cheryl Pegus & SCAN Health Plan’s Dr. Sachin Jain. Then we’ll hear from Aptar Digital Health’s Sai Shankar and Pierre Laurent in a session all about patients as partners in healthcare. The day will continue with other hot topics for pharma, including health equity, cell and gene therapy, oncology, and pharmacy model disruption.
Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court
Fierce Pharma
NOVEMBER 15, 2022
Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court. fkansteiner. Tue, 11/15/2022 - 08:48.
Edible sensor delivers real-time antiretroviral dosage data
European Pharmaceutical Review
NOVEMBER 17, 2022
An innovative ingestible sensor technology tested in an interventional clinical trial provided HIV patients with real-time antiretroviral dosage data , enabling them to better control their infection. The drug regimen for 130 HIV patients was monitored by the Proteus Digital Health Feedback (PDHF) Information Technology system, which let patients know in real-time when a dose of medication had been taken.
Provention Wins FDA Approval for First Drug to Delay Type 1 Diabetes Progression
MedCity News
NOVEMBER 18, 2022
Type 1 diabetes patients now have a new therapeutic option for the autoimmune disorder. Provention Bio drug Tzeild has received FDA approval for delaying the onset of the most severe stage of this chronic disease.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Dupixent nears EU approval for rare skin disease prurigo nodularis
pharmaphorum
NOVEMBER 14, 2022
Sanofi and Regeneron’s Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA’s human medicines committee (CHMP) has recommended IL-4 and IL-13 inhibitor Dupixent (dupilumab) to treat adults with moderate to severe PN, a disease which causes hard lumps to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.
Apellis' closely watched eye drug gets new FDA goal date after changes to its filing scared investors
Fierce Pharma
NOVEMBER 18, 2022
Apellis' closely watched eye drug gets new FDA goal date after changes to its filing scared investors. aliu. Fri, 11/18/2022 - 11:21.
4 pioneering social media campaigns in pharma this year
PharmaVoice
NOVEMBER 17, 2022
The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate.
With Its New, Outsourced Virtual Care Model, Will the Third Time Be the Charm for Amazon?
MedCity News
NOVEMBER 18, 2022
Instead of building its own network of providers and bringing hybrid care services to employers like it did with Amazon Care, the new Amazon Clinic model is direct-to-consumer and outsources to third-party providers. It will likely be the more successful route for the retailer, after failing with Haven and Amazon Care, experts said.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Meeting MSL training needs in an evolving landscape
pharmaphorum
NOVEMBER 17, 2022
As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important. Healthcare professionals trust MSLs to keep them informed and up-to-date about the latest treatments, especially in fast-moving areas like oncology. But who keeps the MSLs up-to-date, and who makes sure they have the hard and soft skills necessary to be an effective partner for healthcare professionals?
With Sanofi as its marketing partner, Provention Bio grabs long-awaited FDA nod for diabetes drug
Fierce Pharma
NOVEMBER 18, 2022
With Sanofi as its marketing partner, Provention Bio grabs long-awaited FDA nod for diabetes drug. kdunleavy. Fri, 11/18/2022 - 10:21.
Highly Cited Researchers 2022: Using deeper qualitative analysis to help spot research misconduct
Clarivate
NOVEMBER 15, 2022
Today we reveal our annual list of Highly Cited Researchers. This year we recognize 6,938 scientists and social scientists who demonstrate significant and broad influence among their peers in their chosen field or fields of research. The exceptional individuals designated Highly Cited Researchers 2022 have published multiple highly cited papers, ranking in the top 1% by citations for field and year over the last decade.
LG, Amwell Launch New Healthcare TV Kit to Fight Burnout and Workforce Shortages
MedCity News
NOVEMBER 17, 2022
LG launched the first solution to come from its collaboration with Amwell. The product, called the Carepoint TV Kit 200L, is in beta testing but will soon be sold to hospitals to help clinicians virtually connect to patients’ rooms. Powered by Amwell’s Converge platform, the product is aimed at helping clinicians more easily engage with patients amid healthcare’s workforce shortage crisis.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
NICE recommends new treatment for EGFR-positive lung cancer
European Pharmaceutical Review
NOVEMBER 17, 2022
Final draft guidance published by the National Institute for Health and Care Excellence (NICE), recommends Mobocertinib (Exkivity), a new therapy that helps slow cancer growth in adults with epidermal growth factor receptor ( EGFR ) exon 20+ non-small-cell lung cancer (NSCLC), who have already received platinum-based chemotherapy. The treatment , produced by Takeda helps to addresses a clear unmet clinical need, as there is currently no standard treatment for the disease.
Takeda's Iclusig delivers a win in rare subtype of acute lymphoblastic leukemia
Fierce Pharma
NOVEMBER 17, 2022
Takeda's Iclusig delivers a win in rare subtype of acute lymphoblastic leukemia. kdunleavy. Thu, 11/17/2022 - 10:29.
Kidney Cancer UK receives commission from NICE
PharmaTimes
NOVEMBER 18, 2022
The charity commissioned a two-year service quality audit of over 18,000 kidney cancer patients
Evernorth Exec: Healthcare Access Will Be the Greatest Problem for Consumers and Employers
MedCity News
NOVEMBER 17, 2022
To combat this issue, Joan Harvey of Evernorth stressed the importance of an omnichannel care model that leverages both in-person and virtual care. She made these comments at the HLTH conference in Las Vegas.
Let's personalize your content